autologous RNA-loaded dendritic cell vaccine

The autologous RNA-loaded dendritic cell vaccine is an investigational, patient-specific immunotherapy developed by Radboud University Medical Center (Radboud UMC) for the treatment of multiple myeloma. This cell-based biologic involves harvesting a patient's own peripheral blood monocytes, differentiating them into dendritic cells, and loading them with tumor-derived RNA that encodes myeloma-associated antigens. The resulting vaccine is administered via intravenous and intradermal routes to stimulate a T-cell mediated immune response against myeloma cells. Clinical evaluation has focused on safety, immune activation, and the reduction of minimal residual disease (MRD) in patients with multiple myeloma.

Other names

RNA-loaded dendritic cell vaccinationautologous RNA-transfected dendritic cells